Apogee Therapeutics reported initial data for its experimental drug APG777 for the treatment of atopic dermatitis, a common inflammatory skin disease. This antibody drug significantly reduced the signs and symptoms of the disease compared to placebo and met the objectives of the mid-phase clinical trial. In a head-to-head comparison, APG777 achieved similar skin clearing rates to existing drugs Dupixent from Sanofi and Regeneron or Ebglyss from Eli Lilly. APG777 is designed for quarterly or biannual injections, which is less frequent than the bimonthly or monthly injections of competing drugs. The data comes from part A of a 16-week phase 2 study where relief of itching and skin manifestations was demonstrated. If the effectiveness is confirmed in later studies, the drug could be more convenient for patients.